Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ALMS

Alumis Inc

Dec 13 • 04:00PM ET

8.39

Dollar change -0.34
Percentage change -3.89	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN GILD REGN VRTX BIIB MRNA INCY BMY ABBV PFE

| Held by: VTI IWM VXF IWO VTWO SCHA IWN IWC SCHB VTWG

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-4.47	Insider Own	45.53%	Shs Outstand	47.22M	Perf Week	-6.78%
Market Cap	438.70M	Forward P/E	-	EPS next Y	-	Insider Trans	45.99%	Shs Float	29.64M	Perf Month	-22.39%
Income	-238.77M	PEG	-	EPS next Q	-1.31	Inst Own	33.56%	Short Float	8.20%	Perf Quarter	-24.07%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	50.79%	Short Ratio	15.52	Perf Half Y	-
Book/sh	6.40	P/B	1.31	EPS next Y	-	ROA	-	Short Interest	2.43M	Perf Year	-
Cash/sh	6.92	P/C	1.21	EPS next 5Y	-	ROE	-	52W Range	7.66 - 13.53	Perf YTD	-36.92%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-63.16%	52W High	-37.99%	Beta	-
Dividend TTM	-	Quick Ratio	11.26	Sales past 5Y	0.00%	Gross Margin	-	52W Low	9.53%	ATR (14)	0.80
Dividend Ex-Date	-	Current Ratio	11.26	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	40.12	Volatility	6.93% 11.06%
Employees	-	Debt/Eq	0.09	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.17	Target Price	30.00
Option/Short	No / Yes	LT Debt/Eq	0.09	EPS Q/Q	-104.55%	Payout	-	Rel Volume	0.49	Prev Close	8.73
Sales Surprise	-	EPS Surprise	2.72%	Sales Q/Q	-	Earnings	Nov 13 AMC	Avg Volume	156.57K	Price	8.39
SMA20	-6.38%	SMA50	-19.17%	SMA200	-26.09%	Trades		Volume	76,812	Change	-3.89%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-31-24	Initiated	Robert W. Baird	Outperform	$25
Oct-17-24	Initiated	H.C. Wainwright	Buy	$30
Jul-23-24	Initiated	Morgan Stanley	Overweight	$36
Jul-23-24	Initiated	Leerink Partners	Outperform	$29
Jul-23-24	Initiated	Guggenheim	Buy	$32
Jul-23-24	Initiated	Cantor Fitzgerald	Overweight

Nov-14-24 04:05PM	Alumis Presents Data Highlighting ESK-001's Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024 (GlobeNewswire) -12.95% -5.95%
Nov-13-24 04:05PM	Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements (GlobeNewswire)
Nov-04-24 08:00AM	Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference (GlobeNewswire)
Sep-27-24 09:00AM	Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study (GlobeNewswire) -6.77%
Sep-03-24 04:29PM	Alumis to Participate in Upcoming September Investor Conferences (GlobeNewswire)
04:05PM	Loading…
Aug-13-24 04:05PM	Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements (GlobeNewswire)
Jul-29-24 08:00AM	Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis (GlobeNewswire)
Jun-27-24 11:57PM	Alumis Announces Pricing of Initial Public Offering (GlobeNewswire)

Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Foresite Labs, LLC	10% Owner	Jul 01 '24	Buy	16.00	2,500,000	40,000,000	5,584,889	Jul 03 09:31 PM
Foresite Capital Management V,	10% Owner	Jul 01 '24	Buy	16.00	2,500,000	40,000,000	5,584,889	Jul 03 09:30 PM
Tananbaum James B.	Director	Jul 01 '24	Buy	16.00	2,500,000	40,000,000	5,584,889	Jul 03 09:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALMS

Alumis Inc

Upgrade your FINVIZ experience